<DOC>
	<DOCNO>NCT02123524</DOCNO>
	<brief_summary>This Phase III , randomize , placebo control , blind , parallel two arm , multicentre trial compare rivaroxaban 10mg daily placebo patient symptomatic leg Superficial Vein Thrombosis ( &gt; = 5cm ) otherwise would initially treat anticoagulant therapy .</brief_summary>
	<brief_title>Rivaroxaban Anticoagulation Superficial Vein Thrombosis</brief_title>
	<detailed_description>Patients symptomatic superficial leg thrombosis randomize two arm , ) rivaroxaban 10mg 1 tablet daily 45 day b ) placebo determine rivaroxaban ( 10 mg daily ) effective safe treatment superficial vein thrombosis .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Symptomatic Superficial Vein Thrombosis leg â‰¥5 cm length ( diagnose clinically ultrasound ) Age &lt; 18 year Symptoms &gt; 42 day Receiving anticoagulant another indication ( example : atrial fibrillation ) Superficial Vein Thrombosis start . Superficial Vein Thrombosis already treat 3 day anticoagulation ( example . fondaparinux Low Molecular Weight Heparin ) . Planned treatment Superficial Vein Thrombosis course anticoagulant therapy . Another indication anticoagulant therapy ( example . Deep Vein Thrombosis , Pulmonary Embolism , atrial fibrillation ) . Judged require immediate ligation saphenofemoral junction strip thrombose varicose vein . proximal Deep Vein Thrombosis Pulmonary Embolism within past 12 month . Superficial Vein Thrombosis associate sclerotherapy intravenous canula . A high risk bleed evidence follow : 1 . Active bleed 2 . Bleeding within past 30 day due cause fully resolve . 3 . Known expected thrombocytopenia platelet count le 80,000 x 10 9/L . 4 . History ever spontaneous intracranial bleeding , intracranial bleeding within past 3 month . 5 . Receiving dual antiplatelet therapy ( example . aspirin clopidogrel ) . Elevated creatinine level suspect creatinine clearance estimate , OR creatinine clearance ( CockcroftGault equation ) less 30 ml/min . Clinically relevant hepatic disease ( include ChildPugh B C ) know suspect ( example. , associate : International Normalized Ratio &gt; 1.7 ; total bilirubin &gt; 2 upper limit normal ; Alanine aminotransferase ( ALT ) Aspartate aminotransferase ( AST ) &gt; 3 time upper limit normal ) . Ongoing requirement systemic treatment azoleantimycotics ( except fluconazole ) , Human Immunodeficiency Virus ( HIV ) protease inhibitor , strong Cytochrome P450 3A4 ( CYP3A4 ) inducer due potential interaction rivaroxaban . Pregnant lactate woman , risk become pregnant . Life expectancy le 90 day Patient unwilling unable comply protocol ( example . unable attend followup visit geographic inaccessibility ) . Participating compete clinical investigation receive investigational agent ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Superficial Vein Thrombosis</keyword>
</DOC>